TIFA Polyklonale Antilichaam, Cy7 Vervoeging

Adapter protein which mediates the IRAK1 and TRAF6 interaction following IL-1 stimulation, resulting in the downstream activation of NF-kappa-B and AP-1 pathways. Induces the oligomerization and polyubiquitination of TRAF6, which leads to the activation of TAK1 and IKK through a proteasome-independent mechanism.

Putative MAPK activating protein PM14; Putative MAPK-activating protein PM14; Putative NF kappa B activating protein 20; Putative NF-kappa-B-activating protein 20; T2BP; TA; TA_HUMAN; TRAF interacting protein with FHA domain containing protein A; TRAF-interacting protein with FHA domain-containing protein A; TRAF2 binding protein; TRAF2-binding protein.

Cytoplasm, Nucleus

Mouse

51-150/184

TIFA

Cy7

KLH conjugated synthetic peptide derived from human TIFA

WB, IF (IHC-P), IF (IHC-F), IF (ICC)

Purified by Protein A.

743nm/767nm

1µg/µl

WB (1:300-5000), IF (IHC-P) (1:50-200), IF (IHC-F) (1:50-200), IF (ICC) (1:50-200)

Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Unmodified

Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Human, Rat, Dog, Cow, Sheep, Pig, Chicken